Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting

Fatigue is a significant symptom in multiple sclerosis (MS) patients. First-generation disease modifying therapies (DMTs) are at best moderately effective to improve fatigue. Observations from small cohorts have indicated that natalizumab, an antibody targeting VLA-4, may reduce MS-related fatigue....

Descripción completa

Detalles Bibliográficos
Autores principales: Svenningsson, Anders, Falk, Eva, Celius, Elisabeth G., Fuchs, Siegrid, Schreiber, Karen, Berkö, Sara, Sun, Jennifer, Penner, Iris-Katharina, for the TYNERGY trial investigators
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605436/
https://www.ncbi.nlm.nih.gov/pubmed/23555589
http://dx.doi.org/10.1371/journal.pone.0058643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605436/
https://www.ncbi.nlm.nih.gov/pubmed/23555589
http://dx.doi.org/10.1371/journal.pone.0058643

Ejemplares similares